ADIAL PHARMACEUTICALS, INC. — Investor Relations & Filings
Filings indexed
519
across all filing types
Latest filing
2026-03-03
Regulatory Filings
Country
US
United States of America
Listing
US
ADIL
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The company's lead investigational drug candidate is AD04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (AUD). AD04 is being developed in conjunction with a proprietary companion diagnostic genetic test. This test is designed to identify patients with specific genotypes who are most likely to respond to the treatment, representing a personalized medicine approach to managing addiction.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer) | 2026-03-03 | English | |
| 8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer) | 2026-02-24 | English | |
| 8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer) | 2026-02-04 | English | |
| CURRENT REPORT | 2026-01-06 | English | |
| DEFINITIVE PROXY STATEMENT | 2026-01-06 | English | |
| PRELIMINARY PROXY STATEMENT | 2025-12-23 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 32892978 | 8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer) | 2026-03-03 | English | ||
| 32892980 | 8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer) | 2026-02-24 | English | ||
| 32892979 | 8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer) | 2026-02-04 | English | ||
| 12425774 | CURRENT REPORT | 2026-01-06 | English | ||
| 12425775 | DEFINITIVE PROXY STATEMENT | 2026-01-06 | English | ||
|
2025
10 filings
| |||||
| 12425776 | PRELIMINARY PROXY STATEMENT | 2025-12-23 | English | ||
| 12425777 | PROSPECTUS SUPPLEMENT | 2025-12-19 | English | ||
| 12425778 | Regulatory Filings 2025 | 2025-12-18 | English | ||
| 12425779 | REGISTRATION STATEMENT | 2025-12-12 | English | ||
| 12425780 | Regulatory Filings 2025 | 2025-12-03 | English | ||
| 12425781 | CURRENT REPORT | 2025-12-01 | English | ||
| 12425782 | CURRENT REPORT | 2025-11-14 | English | ||
| 12425783 | QUARTERLY REPORT | 2025-11-13 | English | ||
| 12425784 | CURRENT REPORT | 2025-09-16 | English | ||
| 12425785 | REGISTRATION STATEMENT | 2025-09-09 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
ADIAL PHARMACEUTICALS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35331/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35331 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35331 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35331 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35331}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ADIAL PHARMACEUTICALS, INC. (id: 35331)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.